🔹 Q4 Revenue: DKK 85.68B (Est. DKK 80.29B) 🟢
🔹 Q4 Wegovy Sales: DKK 19.9B; More than doubled YoY
🔹 FY Revenue: DKK 290.40B (Est. DKK 285.57B) 🟢; UP +25% YoY
🔹 FY EBIT: DKK 128.34B (Est. DKK 125.96B) 🟢
Regional Breakdown:
🔹 North America Revenue: UP +30% YoY
🔹 International Operations Revenue: UP +17% YoY
Q4 Operating Metrics:
🔹 Operating Profit: DKK 36.7B (Est. DKK 33.6B) 🟢; UP +37% YoY
FY'25 Outlook:
🔹 Sales Growth: 16%-24% at CER
🔹 Operating Profit Growth: 19%-27% at CER
🔹 Sales and profit growth in DKK expected to be 3pp and 5pp higher than CER
Operational & Strategic Updates:
🔸 Completed acquisition of three Catalent manufacturing sites
🔸 R&D Progress: CagriSema and Semaglutide trials show superior weight loss efficacy
🔸 Dividend: Board to propose DKK 7.90/share final dividend (Total 2024 dividend: DKK 11.40/share, UP +21% YoY)
CEO Lars Fruergaard Jørgensen's Commentary:
🔸 "Strong 2024 performance with 26% sales growth, benefiting over 45M people globally. Focus remains on commercial execution, expanding R&D pipeline, and scaling production capacity in 2025."